ADORA3 and hepatocellular carcinoma: Investigation of 3,7-dihydro-1H-purine-2,6-dione structural moiety as a potential scaffold to target adenosine 3 receptors (ADORA3) modulator towards treatment of hepatocellular carcinoma directed us to re-purpose LIN, already FDA approved anti-diabetic drug with established safety profile, as adenosine 3 receptors (ADORA3) modulator targeting hepatocellular carcinoma, in addition to its oxidative product.